Evidence map›Paper›PMID 31158233›Full record

ArticlePloS one2019

RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.

Joseph L Bundy, Blair R Anderson, Ludmila Francescatto, Melanie E Garrett, Karen L Soldano, Marilyn J Telen, Erica E Davis, Allison E Ashley-Koch

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Lessons From APOL1 Animal Models.Frontiers in medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Joseph L BundyDuke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina, United States of America.ORCID 0000-0002-7631-6197
Blair R AndersonDuke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Ludmila FrancescattoCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
Melanie E GarrettDuke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Karen L SoldanoDuke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Marilyn J TelenDepartment of Medicine, Duke University Medical Center, Durham, North Carolina, United States of America.
Erica E DavisCenter for Human Disease Modeling, Duke University Medical Center, Durham, North Carolina, United States of America.
Allison E Ashley-KochDuke Molecular Physiology Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Duke Medical Center · US

Funding

TRANSFUSION MEDICINE AND RELATED AREAST32HL007057 · NHLBI · DUKE UNIVERSITY · PI Gowthami M Arepally · 1985 to 2026
$10.6M
Transcriptomic, therapeutic and genetic investigations of sickle cell nephropathyR01DK110104 · NIDDK · DUKE UNIVERSITY · PI ASHLEY-KOCH, ALLISON E, DAVIS, ERICA ELLEN · 2016 to 2018
$716k
NHLBI NIH HHS T32 HL007057NIDDK NIH HHS R01 DK110104
6 · The paper itself

Abstract

Kidney failure occurs in 5-13% of individuals with sickle cell disease and is associated with early mortality. Two APOL1 alleles (G1 and G2) have been identified as risk factors for sickle cell disease nephropathy. Both risk alleles are prevalent in individuals with recent African ancestry and have been associated with nephropathic complications in other diseases. Despite the association of G1 and G2 with kidney dysfunction, the mechanisms by which these variants contribute to increased risk remain poorly understood. Previous work in zebrafish models suggest that the G2 risk allele functions as a dominant negative, whereas the G1 allele is a functional null. To understand better the cellular pathology attributed to APOL1 G2, we investigated the in vivo effects of the G2 risk variant on distinct cell types using RNA sequencing. We surveyed APOL1 G2 associated transcriptomic alterations in podocytes and vascular endothelial cells isolated from zebrafish larvae expressing cell-type specific reporters. Our analysis identified many transcripts (n = 7,523) showing differential expression between APOL1 G0 (human wild-type) and APOL1 G2 exposed podocytes. Conversely, relatively few transcripts (n = 107) were differentially expressed when comparing APOL1 G0 and APOL1 G2 exposed endothelial cells. Pathway analysis of differentially expressed transcripts in podocytes showed enrichment for autophagy associated terms such as "Lysosome" and "Phagosome", implicating these pathways in APOL1 G2 associated kidney dysfunction. This work provides insight into the molecular pathology of APOL1 G2 nephropathy which may offer new therapeutic strategies for multiple disease contexts such as sickle cell nephropathy.

Indexed as

Genetic VariationSequence Analysis, RNAZebrafishAnemia, Sickle CellAnimalsApolipoprotein L1Gene ExpressionGenetic Predisposition to DiseaseHumansKidney DiseasesLarvaPodocytesRiskRNA, MessengerTranscription, GeneticAPOL1 protein, humanApolipoprotein L1RNA, Messenger

Identifiers

PMID31158233
PMCPMC6546218
OpenAlexW2948926562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.